Advanced or Metastatic Breast Cancer research hub
4 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
United States · Argentina · Australia - active not recruitingPHASE2
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
This study looks at a new drug, PF-07220060, combined with fulvestrant for advanced or metastatic breast cancer. It compares this combination to standard treatments to see if it's safe and effective for people whose cancer has progressed after previous therapies.
United States · Argentina · Australia - ongoing, recruitingPhase I and Phase II (Integrated)- Other
C4891024 - TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY C (ARV-471 IN COMBINATION WITH SAMURACICLIB)
This study is testing a new combination treatment for advanced or metastatic breast cancer. It combines a drug called vepdegestrant (ARV-471) with samuraciclib. Researchers are looking at how safe and effective this new combination is for people aged 18 and over.
Italy · Spain · France - recruitingPHASE2
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
This study looks at adding a drug called elacestrant to olaparib for patients with a certain type of advanced breast cancer and a BRCA gene change. It hopes to see if this combination works better than olaparib alone.
Germany